Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Podcasts|January 29, 2021
Navitus: a 'Full Pass-Through' PBM Working to Improve Medication Adherence
Author(s)Briana Contreras
MHE Associate Editor Briana Contreras and Senior Editor Peter Wehrwein speak with Julie Olson, senior director of Population Health and Product Development at Navitus, a full pass-through pharmacy benefits management (PBM) company. In this discussion they talked about how Navitus has created a Clinical Engagement Center designed to improve medication adherence and reduce both member and plan prescription costs, while easing benefit transitions. Additionally, they discussed what it means to be a “full pass-through” PBM and how it compares to other PBMs.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on
Advertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
4
Jessica Castle, M.D., discusses CGM’s A1C impact in non-insulin type 2 diabetes
5